Literature DB >> 24928666

Evaluating the potential impact of mass praziquantel administration for HIV prevention in Schistosoma haematobium high-risk communities.

Martial L Ndeffo Mbah1, Jennifer A Gilbert2, Alison P Galvani3.   

Abstract

Genital infection with Schistosoma haematobium is prevalent in sub-Saharan Africa. Epidemiological studies have observed that genital schistosomiasis is associated with an increased odd of HIV infection among women. We used mathematical modeling to explore the potential impact of mass preventive chemotherapy against schistosomiasis on HIV transmission in three sub-Saharan Africa countries: Angola, Kenya, and Zambia. We developed a model of female genital schistosomiasis (FGS) and HIV transmission dynamics, fitting it to data of HIV and S. haematobium prevalences as well as co-infection. We simulated targeted mass drug administration (MDA) with praziquantel to school-age children and mass treatment of the entire community. We estimated that, in S. haematobium high-risk communities, targeted annual treatment of school-age children could reduce HIV prevalence by 20% (95% CI: 12-31%) in Angola, 16% (95% CI: 10-32%) in Kenya, and 6% (95% CI: 3-18%) in Zambia after the first 20 years of intervention; and would reduce HIV incidence by 15% (95% CI: 13-32%) in Angola, 22% (95% CI: 18-42%) in Kenya, and 9% (95% CI: 3-22%) in Zambia. Extending the intervention to adults could reduce HIV prevalence by an additional 2.2% (95% CI: 0.2-12.0%) in Angola, 1.8% (95% CI: 0.1-5.2%) in Kenya, and 0.3% (95% CI: 0.1-2.1%) in Zambia; and would reduce HIV incidence by an additional 1.8% (95% CI: 0.0-14.4%) in Angola, 6.1% (95% CI: 0.5-12.6%) in Kenya, and 0.8% (95% CI: 0.0-2.7%) in Zambia. We showed that the exacerbation of HIV transmission due to FGS and the probability of developing FGS as a result of childhood infection with S. haematobium, were the most important factors in determining the effectiveness of praziquantel MDA for reducing HIV transmission. Praziquantel MDA may be an innovative measure for reducing schistosomiasis and HIV transmission in sub-Saharan Africa, the effectiveness of which varies with HIV prevalence.
Copyright © 2014 The Authors. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Female genital schistosomiasis; HIV; Mathematical modeling; Praziquantel; Schistosoma haematobium

Mesh:

Substances:

Year:  2014        PMID: 24928666      PMCID: PMC4316832          DOI: 10.1016/j.epidem.2014.04.002

Source DB:  PubMed          Journal:  Epidemics        ISSN: 1878-0067            Impact factor:   4.396


  33 in total

Review 1.  Antiretroviral therapy to treat and prevent HIV/AIDS in resource-poor settings.

Authors:  Geoff P Garnett; Lucy Bartley; Nicholas C Grassly; Roy M Anderson
Journal:  Nat Med       Date:  2002-07       Impact factor: 53.440

Review 2.  A review of female genital schistosomiasis.

Authors:  Eyrun F Kjetland; Peter D C Leutscher; Patricia D Ndhlovu
Journal:  Trends Parasitol       Date:  2012-01-12

3.  Genital schistosomiasis in women: a clinical 12-month in vivo study following treatment with praziquantel.

Authors:  Eyrun F Kjetland; Takafira Mduluza; Patricia D Ndhlovu; Exenevia Gomo; Lovemore Gwanzura; Nicholas Midzi; Peter R Mason; Henrik Friis; Svein Gunnar Gundersen
Journal:  Trans R Soc Trop Med Hyg       Date:  2006-01-10       Impact factor: 2.184

4.  Schistosomiasis and HIV-1 infection in rural Zimbabwe: effect of treatment of schistosomiasis on CD4 cell count and plasma HIV-1 RNA load.

Authors:  Per Kallestrup; Rutendo Zinyama; Exnevia Gomo; Anthony E Butterworth; Boniface Mudenge; Govert J van Dam; Jan Gerstoft; Christian Erikstrup; Henrik Ullum
Journal:  J Infect Dis       Date:  2005-10-20       Impact factor: 5.226

5.  Cost-effectiveness of a successful schistosomiasis control programme in Cambodia (1995-2006).

Authors:  Davide Croce; Emanuele Porazzi; Emanuela Foglia; Umberto Restelli; Muth Sinuon; Duong Socheat; Antonio Montresor
Journal:  Acta Trop       Date:  2009-12-03       Impact factor: 3.112

6.  Prevention of gynecologic contact bleeding and genital sandy patches by childhood anti-schistosomal treatment.

Authors:  Eyrun Floerecke Kjetland; Patricia D Ndhlovu; Edith Nyaradzai Kurewa; Nicholas Midzi; Exnevia Gomo; Takafira Mduluza; Henrik Friis; Svein Gunnar Gundersen
Journal:  Am J Trop Med Hyg       Date:  2008-07       Impact factor: 2.345

Review 7.  Examining the relationship between urogenital schistosomiasis and HIV infection.

Authors:  Pamela Sabina Mbabazi; Olivia Andan; Daniel W Fitzgerald; Lester Chitsulo; Dirk Engels; Jennifer A Downs
Journal:  PLoS Negl Trop Dis       Date:  2011-12-06

8.  Evidence against rapid emergence of praziquantel resistance in Schistosoma haematobium, Kenya.

Authors:  C H King; E M Muchiri; J H Ouma
Journal:  Emerg Infect Dis       Date:  2000 Nov-Dec       Impact factor: 6.883

9.  Africa's 32 cents solution for HIV/AIDS.

Authors:  Peter J Hotez; Alan Fenwick; Eyrun F Kjetland
Journal:  PLoS Negl Trop Dis       Date:  2009-05-26

10.  Potential cost-effectiveness of schistosomiasis treatment for reducing HIV transmission in Africa--the case of Zimbabwean women.

Authors:  Martial L Ndeffo Mbah; Eric M Poolman; Katherine E Atkins; Evan W Orenstein; Lauren Ancel Meyers; Jeffrey P Townsend; Alison P Galvani
Journal:  PLoS Negl Trop Dis       Date:  2013-08-01
View more
  11 in total

1.  Something old, something new: is praziquantel enough for schistosomiasis control?

Authors:  W Evan Secor; Susan P Montgomery
Journal:  Future Med Chem       Date:  2015       Impact factor: 3.808

Review 2.  Prostate adenocarcinoma associated with prostatic infection due to Schistosoma haematobium. Case report and systematic review.

Authors:  Jacinta Chaves Figueiredo; Joachim Richter; Nilo Borja; Antonino Balaca; Sandra Costa; Silvana Belo; Maria Amélia Grácio
Journal:  Parasitol Res       Date:  2014-12-30       Impact factor: 2.289

3.  Interactions of Schistosoma and HIV in Sub-Saharan Africa: A Systematic Review.

Authors:  Briana D Furch; John R Koethe; Violet Kayamba; Douglas C Heimburger; Paul Kelly
Journal:  Am J Trop Med Hyg       Date:  2020-04       Impact factor: 2.345

4.  Halting Schistosoma haematobium - associated bladder cancer.

Authors:  Monica C Botelho; Helena Alves; Joachim Richter
Journal:  Int J Cancer Manag       Date:  2017-09-30

5.  Evaluating long-term effectiveness of sleeping sickness control measures in Guinea.

Authors:  Abhishek Pandey; Katherine E Atkins; Bruno Bucheton; Mamadou Camara; Serap Aksoy; Alison P Galvani; Martial L Ndeffo-Mbah
Journal:  Parasit Vectors       Date:  2015-10-22       Impact factor: 3.876

6.  Knowledge and awareness of genital involvement and reproductive health consequences of urogenital schistosomiasis in endemic communities in Ghana: a cross-sectional study.

Authors:  Dzidzo R Yirenya-Tawiah; Mercy M Ackumey; Kwabena M Bosompem
Journal:  Reprod Health       Date:  2016-09-21       Impact factor: 3.223

Review 7.  Impact of Endemic Infections on HIV Susceptibility in Sub-Saharan Africa.

Authors:  Sergey Yegorov; Vineet Joag; Ronald M Galiwango; Sara V Good; Brenda Okech; Rupert Kaul
Journal:  Trop Dis Travel Med Vaccines       Date:  2019-11-29

Review 8.  Modelling microbial infection to address global health challenges.

Authors:  Meagan C Fitzpatrick; Chris T Bauch; Jeffrey P Townsend; Alison P Galvani
Journal:  Nat Microbiol       Date:  2019-09-20       Impact factor: 17.745

Review 9.  Beyond the barrier: Female Genital Schistosomiasis as a potential risk factor for HIV-1 acquisition.

Authors:  A S Sturt; E L Webb; S C Francis; R J Hayes; A L Bustinduy
Journal:  Acta Trop       Date:  2020-05-13       Impact factor: 3.112

10.  Association of schistosomiasis and HIV infections: A systematic review and meta-analysis.

Authors:  Pragna Patel; Charles E Rose; Eyrun F Kjetland; Jennifer A Downs; Pamela Sabina Mbabazi; Keith Sabin; Wairimu Chege; D Heather Watts; W Evan Secor
Journal:  Int J Infect Dis       Date:  2020-11-03       Impact factor: 3.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.